ULTRAGENYX PHARMACEUTICAL INC. Effect of Exchange Rate on Cash, Continuing Operations
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Effect of Exchange Rate on Cash, Continuing Operations of $249.00 thousand for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-08.
Discontinued › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashContinuingOperations · last filed 2018-05-08
- ULTRAGENYX PHARMACEUTICAL INC. effect of exchange rate on cash, continuing operations for the quarter ending 2018-03-31 was $249.00K, a 1364.71% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. effect of exchange rate on cash, continuing operations for the quarter ending 2017-03-31 was $17.00K.
- ULTRAGENYX PHARMACEUTICAL INC. effect of exchange rate on cash, continuing operations for fiscal 2017 was $528.00K.
- ULTRAGENYX PHARMACEUTICAL INC. effect of exchange rate on cash, continuing operations for fiscal 2016 was -$65.00K.
| Period end | Effect of Exchange Rate on Cash, Continuing Operations 3 month | Effect of Exchange Rate on Cash, Continuing Operations 6 month | Effect of Exchange Rate on Cash, Continuing Operations 9 month | Effect of Exchange Rate on Cash, Continuing Operations 12 month |
|---|---|---|---|---|
| 2018-03-31 | $249.00K 10-Q · filed 2018-05-08 | |||
| 2017-12-31 | $528.00K 10-K · filed 2018-02-21 | |||
| 2017-09-30 | $167.00K 10-Q · filed 2017-11-03 | |||
| 2017-06-30 | -$361.00K 10-Q · filed 2017-07-28 | |||
| 2017-03-31 | $17.00K 10-Q · filed 2018-05-08 | |||
| 2016-12-31 | -$65.00K 10-K · filed 2018-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |